Workflow
奥赛康(002755) - 2015 Q3 - 季度财报
ASK PHARMASK PHARM(SZ:002755)2015-10-29 16:00

Financial Performance - Operating revenue decreased by 66.44% to ¥27,506,438.07 compared to the same period last year[6] - Net profit attributable to shareholders increased by 942.38% to ¥441,455.50 compared to the same period last year[6] - Basic earnings per share increased by 450.00% to ¥0.044 compared to the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥41,820,121.60, a decrease of 79.37% compared to the same period last year[6] - The estimated net profit attributable to shareholders for 2015 is expected to range from 18.75 million to 30.00 million RMB, representing a decrease of 20% to 50% compared to 37.50 million RMB in 2014[15] - The decline in performance is attributed to the continued sluggishness of large new projects in the petrochemical industry and intense competition in geotechnical and surveying engineering markets[15] Assets and Shareholder Equity - Total assets increased by 19.41% to ¥695,724,342.84 compared to the end of the previous year[6] - Net assets attributable to shareholders increased by 52.77% to ¥509,672,136.18 compared to the end of the previous year[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,097[10] - The largest shareholder, Chen Huili, holds 8.04% of the shares, totaling 8,148,684 shares[10] - The company did not conduct any repurchase transactions during the reporting period[11] Return on Equity - Weighted average return on equity decreased by 13.55% to 4.58% year-to-date[6]